New Crystalline Forms Of N-(3-(2-(2-Hydroxyethoxy)-6-Morpholinopyridin-4-Yl)-4-Methvlphenyl)-2(Trifluoromethyl) Isonicotinamide As Raf Inhibitors For The Treatment Of Cancer - EP4563150
The patent EP4563150 was granted to Novartis on Jul 23, 2025. The application was originally filed on May 12, 2020. The patent is currently recorded with a legal status of "Pending".
EP4563150
- Filing Date
- May 12, 2020
- Status
- Pending
- Grant Date
- Jul 23, 2025
- External Links
- Slate, Register, Google Patents
Patent Summary
Patent Family
Dossier Documents
The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.
Get instant alerts for new documents